

United States Patent and Trademark Office

ess:	COMMISSIONER FOR PATENTS
	P.O. Box 1450
	Alexandria, Virginia 22313-1450
	www.uspto.gov

APPLICATION NO.		FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.	
10/087,469		03/01/2002	Raymond A. Hui	9793/96 (RDID 01061)	6651	
23690	7590	09/11/2006		EXAMINER		
Roche Diagnostics Corporation, Inc.				CEPERLEY, MARY		
9115 Hague Road PO Box 50457				ART UNIT	PAPER NUMBER	
	Indianapolis, IN 46250-0457			1641		
				DATE MAILED: 09/11/2006		

Please find below and/or attached an Office communication concerning this application or proceeding.

		Application No.	Applicant(s)					
Office Action Summary		10/087,469	HUI, RAYMOND A.					
		Examiner	Art Unit					
		Mary (Molly) E. Ceperley	1641					
Period fo	The MAILING DATE of this communication ap or Reply	pears on the cover sheet with the c	correspondence ad	ddress				
A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION. - Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication. - If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication. - Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).								
Status								
1)[Responsive to communication(s) filed on 24 J	lulv 2006						
3)	Since this application is in condition for allowa		osecution as to th	e merits is				
,—	closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11, 453 O.G. 213.							
Disposit	ion of Claims	•						
4)⊠	Claim(s) <u>1-15,19-24,26,27,32,33,48 and 51-5</u>	5 is/are pending in the application	ı .					
	4a) Of the above claim(s) is/are withdra							
5)⊠	Claim(s) 1-15 and 51-53 is/are allowed.							
6)⊠	•							
7)[Claim(s) is/are objected to.							
8)[Claim(s) are subject to restriction and/o	or election requirement.						
Applicati	ion Papers	•						
9)[The specification is objected to by the Examin	er.						
•	The drawing(s) filed on is/are: a) acc		Examiner.					
	Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).							
	Replacement drawing sheet(s) including the correct	ction is required if the drawing(s) is ob	jected to. See 37 C	FR 1.121(d).				
11)	The oath or declaration is objected to by the E	xaminer. Note the attached Office	Action or form P	TO-152.				
Priority ι	ınder 35 U.S.C. § 119							
	Acknowledgment is made of a claim for foreigi ☐ All _ b)☐ Some * c)☐ None of:	n priority under 35 U.S.C. § 119(a))-(d) or (f).					
۵,,	1. Certified copies of the priority documen	ts have been received.						
	2. Certified copies of the priority documents have been received in Application No							
	3. Copies of the certified copies of the price	• • • • • • • • • • • • • • • • • • • •		Stage				
	application from the International Burea	u (PCT Rule 17.2(a)).		-				
* See the attached detailed Office action for a list of the certified copies not received.								
Attachmen		_						
	e of References Cited (PTO-892) e of Draftsperson's Patent Drawing Review (PTO-948)	4) 🔲 Interview Summary Paper No(s)/Mail Da						
	e of Draftsperson's Patent Drawing Review (P10-948) nation Disclosure Statement(s) (PTO/SB/08)	5) Notice of Informal F						
	r No(s)/Mail Date	6) 🔲 Other:						

1) It is suggested that the following terms be removed from the noted claims since these terms are redundant with the terminology used in the independent claims.

In claims 6, 11 and 13, delete the definition of "R₂".

In claim 7, delete definition of "M".

It is also noted that claim 24 should apparently be dependent from claim 22 rather than claim 23 since the definition "k is 3" appears in claim 22 rather than in claim 23. See also, claim 7.

2) The following is a quotation of the second paragraph of 35 U.S.C. 112:

The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.

3) Claims 19-21, 32, 33 and 48 are again rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention for the reason stated in paragraph *5)* of the March 02, 2006 Office action.

The proviso of claim 19 that "when M is -O-, T is not H" is inconsistent with the later requirement that "T is a macromolecular carrier".

Applicant's arguments filed July 24, 2006 have been fully considered but they are not persuasive. Contrary to applicant's statement that "applicant has now amended claim 19 to eliminate the recitation", the inconsistency noted above has not been corrected.

- 4) The text of those sections of Title 35, U.S. Code not included in this action can be found in a prior Office action.
- *5)* Claims 19-24, 26, 27, 32, 33, 48, 54 and 55 are rejected under 35 U.S.C. 102(e) as anticipated by or, in the alternative, under 35 U.S.C. 103(a) as obvious over Rouhani et al {US}

2003/0207469} for the reasons of record particularly as stated in paragraph **8**) of the March 02, 2006 Office action and in paragraph **6**) of the June 17, 2005 Office action.

Given the fact that "R²" in claim 19 is defined as "hydrogen" or "an alkyl group" (i.e. "R²" is <u>not</u> a "protecting group"), the claimed immunogen and the antibody produced therefrom are still described by Rouhani et al as set forth in the previous Office actions. Newly presented claim 55 similarly defines "R²" as "H" (and not a "protecting group") which is a definition of the corresponding group "X" in the Rouhani et al immunogens and tracers {see paragraphs [0030] and [0034] of Rouhani et al}.

Applicant's arguments filed July 24, 2006 have been fully considered but they are not persuasive. The amendment to claim 19 to eliminate the dependency of claim 19 on claim 51 does not address the fact that "R²" is defined as "hydrogen" or "an alkyl group" in claim 19; these definitions are included in the Rouhani et al compounds.

- **6)** Claims 1-15 and 51-53 are allowed.
- **7)** Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, **THIS ACTION IS MADE FINAL**. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the date of this final action.

Art Unit: 1641

8) Any inquiry concerning this communication or earlier communications from the examiner should be directed to Mary (Molly) E. Ceperley whose telephone number is (571) 272-0813. The examiner can normally be reached from 8:30 a.m. to 5:00 p.m.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Long V. Le, can be reached on (571) 272-0823. The fax phone number for the organization where this application or proceeding is assigned is (571) 273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

September 01, 2006

Mary E. Ceperley

Mary (Molly) E. Ceperley

Primary Examiner Art Unit 1641